ECV-304 Xenograft Model Service for Bladder Cancer

The ECV-304 xenograft model represents a well-characterized preclinical platform for bladder carcinoma research, offering robust tumorigenicity and epithelial-like morphology ideal for evaluating novel therapeutic strategies. Alfa Cytology leverages this established cell line to deliver reliable, high-quality ECV-304 xenograft model services tailored to accelerate your oncology drug development pipeline.

Overview of ECV-304 Xenograft Model for Bladder Cancer

The ECV-304 cell line, originally cataloged as a spontaneously transformed endothelial model, has been reclassified through DNA fingerprinting and karyotype analysis as genetically identical to the T24 bladder carcinoma line, establishing it as a derivative of human urinary bladder carcinoma. This epithelial-like cell line exhibits characteristic cobblestone morphology at confluent density, robust adherent monolayer growth, and documented tumorigenicity in immunocompromised hosts, making it a valuable preclinical tool for studying bladder cancer progression, angiogenesis mimicry, and therapeutic response. The line carries recurrent somatic mutations in critical oncogenes and tumor suppressor pathways, including documented alterations in HRAS, TERT, and TP53, which contribute to its aggressive proliferative phenotype and serum-independent growth characteristics.

In xenograft applications, ECV-304 tumors demonstrate consistent subcutaneous engraftment with epithelial architecture, forming solid masses that recapitulate key features of bladder carcinoma including rapid proliferation and microvascular interaction. The model has been extensively utilized to investigate tumor plasticity, vasculogenic mimicry, and endothelial-tumor cell interactions, providing a physiologically relevant system for evaluating cytotoxic agents, targeted therapies, and combination regimens. At Alfa Cytology, we optimize ECV-304 xenograft establishment through rigorous cell authentication, standardized inoculation protocols, and comprehensive tumor monitoring to ensure reproducible, publication-ready data for your preclinical studies.

Figure 1. Urinary levels of the mRNA-based tumor marker OP18:UPK1A. (Hanke, M, et al., 2020)

Cell Line Information: ECV-304

The following table summarizes the key characteristics and specifications of the ECV-304 cell line used in our xenograft model service:

Our Services

Alfa Cytology is a dedicated preclinical CRO specializing in tumor model services, and our ECV-304 xenograft platform is built on stringent quality control, authenticated cell stocks, and standardized protocols that ensure consistent tumor take rates and reproducible pharmacodynamic endpoints. Whether your program requires single-agent efficacy assessment, combination therapy evaluation, or biomarker discovery in bladder carcinoma, our experienced scientific team delivers customized study designs with comprehensive tumor monitoring, body weight tracking, and terminal tissue collection to advance your compound from lead optimization to IND-enabling studies.

Workflow of ECV-304 Xenograft Model Construction

Alfa Cytology follows a systematic, quality-controlled workflow for ECV-304 xenograft model construction, ensuring reproducible tumor establishment and reliable data generation. The process begins with authenticated ECV-304 cells expanded under standardized in vitro conditions, followed by controlled inoculation into immunocompromised host mice and comprehensive post-inoculation monitoring until study endpoints are reached.

1. Cell Authentication and Expansion: ECV-304 cells are authenticated via STR profiling and confirmed mycoplasma-free before expansion. Cells are cultured under optimized conditions (37 degrees C, 5% CO2) to log-phase growth, harvested by trypsinization, and resuspended in serum-free medium at a predetermined concentration validated for tumorigenicity.
2. Preparation of Cell Inoculum: The cell suspension is mixed 1:1 with high-concentration Matrigel or PBS-based matrix to enhance engraftment efficiency. Final cell density is adjusted based on pilot studies to achieve consistent tumor take rates while minimizing latency period.
3. Animal Preparation and Inoculation: Immunocompromised mice (athymic nude or NOD-SCID) are acclimated and randomized into study groups. ECV-304 cells are inoculated subcutaneously into the flank region using aseptic technique, with each mouse receiving a standardized volume (typically 100-200 uL) containing the validated cell number.
4. Tumor Monitoring and Randomization: Tumors are monitored by caliper measurement twice weekly beginning from the first palpable detection. Mice are randomized into treatment cohorts once tumors reach the target volume (typically 100-150 mm^3), ensuring uniform baseline tumor burden across all groups.
5. Treatment Administration and Monitoring: Test compounds are administered according to the study design (oral gavage, intraperitoneal, or intravenous). Body weights and tumor dimensions are recorded throughout the treatment phase, with clinical observations documented daily to assess tolerability.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for downstream analysis. Optional endpoints include immunohistochemistry, gene expression profiling, pharmacokinetic sampling, and plasma biomarker analysis to support mechanistic interpretation.

Figure 2. ECV-304 xenograft model construction workflow.

Case Study-ECV-304 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established subcutaneous ECV-304 xenografts in immunocompromised mice to evaluate candidate therapeutic efficacy against bladder carcinoma. Following successful tumor engraftment and randomization, animals received the investigational compound according to a predefined dosing regimen. Throughout the study, tumor growth kinetics, body weight dynamics, and general clinical status were monitored systematically. Preliminary data indicated dose-dependent tumor growth inhibition compared to vehicle controls, with favorable tolerability profiles observed across all treated cohorts. Detailed pharmacodynamic analyses, including tumor tissue biomarker assessments and histopathological evaluations, were conducted at study completion to elucidate mechanism of action and support further development decisions. Specific quantitative results and comprehensive datasets are available upon formal inquiry to protect client confidentiality and intellectual property.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your ECV-304 bladder cancer xenograft studies provides access to a scientifically rigorous, quality-driven preclinical service platform designed to generate decision-enabling data efficiently and reliably.

• Authenticated cell lines with verified STR profiles and comprehensive pathogen screening ensure model integrity from study initiation.
• Standardized xenograft protocols optimized for ECV-304 tumorigenicity deliver consistent tumor take rates and reproducible growth kinetics.
• Customizable study designs accommodate single-agent, combination, dose-response, and biomarker-driven exploratory objectives.
• Real-time tumor monitoring and electronic data capture provide transparent study progress tracking and audit-ready documentation.
• Integrated endpoint analysis including histopathology, IHC, and molecular profiling supports mechanistic and translational research goals.
• Dedicated project management ensures responsive communication, timeline adherence, and scientific consultation throughout your engagement.

Contact Us

Ready to advance your bladder cancer therapeutic program with a validated ECV-304 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and learn how Alfa Cytology can accelerate your preclinical development timeline. Please reach out to us today via our inquiry form or email to learn more about our ECV-304 Xenograft Model services.

For research use only. Not intended for any clinical use.